Latest Endothelin Stories
A new study significantly improves understanding of how widely used drugs in pulmonary arterial hypertension (PAH) affect the heart health of patients who use them.
Bioengineers at Harvard have identified, for the very first time, the mechanism for diffuse axonal injury and explained why cerebral vasospasm is more common in blast-induced brain injuries than in brain injuries typically suffered by civilians.
New findings offer new hope for the treatment of traumatic brain injury (TBI) in veterans wounded by explosions.
SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer. Dr.
Scientists are learning more about how protein gets in the urine when the kidneys begin to fail and how a new drug blocks it.
SOUTH SAN FRANCISCO, Calif., Aug. 25 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the brand name VELETRIÂ® for the company's epoprostenol for injection therapy.
NEW ORLEANS, May 17 /PRNewswire-FirstCall/ -- Actelion Ltd (SIX: ATLN) announced today that findings from the REVEALÂ® (Registry to EValuate Early And Long-term PAH Disease Management) Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension (PAH) according to data presented at the American Thoracic Society's (ATS) Annual International Conference.
SOUTH SAN FRANCISCO, Calif., April 22 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.